Share
1,473 Posts.
lightbulb Created with Sketch. 172
clock Created with Sketch. 23/08/23
13:49
Share
Originally posted by thevinnys:
↑
VIDEO Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) chief medical officer Dr Mark Bleakley speaks with Proactive after the company received clearance from the US Food and Drug Administration (FDA) to begin a Phase 2/3 clinical trial for its IHL-42X asset, designed to address obstructive sleep apnoea (OSA). The clinical-stage pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic-assisted psychotherapies for unmet needs received the approval after submitting an Investigational New Drug (IND) application to the FDA last month. With the milestone approval in the bag, Incannex will proceed with the finalisation of institutional review board applications and submissions for the lead clinical trial sites.
Expand
Hopefully we fully on the nasdaq before any 42x trial update other than safety ect, reckon there will be offers on the table well before the 52 week period has ended. Big boys will either want to take it on or squash it .
